Quarterly Report
Quarterly Report
Brisbane, April 19, 2018 AEST (ABN Newswire) - Anatara Lifesciences (ASX:ANR) today released its Appendix 4C financial report for the quarter ending 31st March 2018.

Anatara Lifesciences is pleased to advise a neutral cash flow for the quarter ending 31st March 2018 and an updated cash balance of $8.76 million as reported in the attached March Appendix 4C.

Anatara Chairman, Dr Mel Bridges said, "Since listing in October 2014, the Anatara team has worked diligently on delivering its key milestones, and is focused on continuing to do so. We are pleased to maintain a strong cash position and appreciate the patience of our shareholders whilst we positively move along the path to delivering shareholder value."

To view the full report, please visit:

About Anatara Lifesciences Ltd

Anatara Lifesciences ASX ANRAnatara Lifesciences (ASX:ANR) is developing therapeutics for gastrointestinal diseases in production animals and humans. Its lead product Detach(R) is a natural plant based product that aids in the control of diarrhoea and will help address global concerns around the overuse of antibiotics in production animals that is contributing to the rise of so-called "super bugs" that make infectious diseases harder to treat. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies.



General inquiries:
Dr Mel Bridges
Executive Chairman
Anatara Lifesciences
Phone: +61-413-051-600
Email: mbridges@anatara.com

Media inquiries:
Jane Lowe
Managing Director
IR Department
Phone: +61-411-117-774
Email: jane.lowe@irdepartment.com.au

Related Companies

Anatara Lifesciences Ltd

ABN Newswire This Page Viewed:  (Last 7 Days: 44) (Last 30 Days: 227) (Since Published: 1955) 

Anatara Lifesciences Ltd NEWS: RECENT VISITS (3560)

Research Report

Social Media